Craig F LaForce

Summary

Publications

  1. ncbi Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma
    Joseph M Parker
    MedImmune LLC, Gaithersburg, MD, USA
    BMC Pulm Med 11:14. 2011
  2. ncbi Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma
    C F LaForce
    North Carolina Clinical Research, Raleigh 27607, USA
    Ann Allergy Asthma Immunol 85:407-15. 2000
  3. ncbi Review of the pharmacology, clinical efficacy, and safety of azelastine hydrochloride
    Craig La Force
    Carolina Allergy and Asthma Consultants, 4301 Lake Boon Trail, Suite 309A, Raleigh, NC 27607, USA
    Expert Rev Clin Immunol 1:191-201. 2005
  4. ncbi Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis
    Craig F LaForce
    North Carolina Clinical Research, Raleigh, North Carolina 27607, USA
    Allergy Asthma Proc 31:132-40. 2010
  5. ncbi Efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol once daily for the treatment of seasonal allergic rhinitis
    Craig LaForce
    North Carolina Clinical Research, Raleigh, North Carolina 27607, USA
    Ann Allergy Asthma Immunol 103:166-73. 2009
  6. ncbi Patient satisfaction with a pressurized metered-dose inhaler with an integrated dose counter containing a fixed-dose mometasone furoate/formoterol combination
    Craig LaForce
    Department of Pediatrics, University of North Carolina School of Medicine, North Carolina Clinical Research, Raleigh, NC, USA
    J Asthma 48:625-31. 2011
  7. ncbi Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine
    Craig F LaForce
    Carolina Allergy and Asthma Consultants, Raleigh, North Carolina 27607, USA
    Ann Allergy Asthma Immunol 93:154-9. 2004
  8. ncbi Montelukast effectively treats the nighttime impact of seasonal allergic rhinitis
    Eli O Meltzer
    Allergy and Asthma Medical Group and Research Center, San Diego, CA 92109, USA
    Am J Rhinol 19:591-8. 2005
  9. ncbi Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma
    Brian J Lipworth
    Allergy Research Group, Department of Medicine and Therapeutics, University of Dundee, Dundee, Scotland
    Ann Allergy Asthma Immunol 94:465-72. 2005
  10. ncbi Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis
    Janet van Adelsberg
    Merck and Co Inc Rahway, New Jersey, USA
    Ann Allergy Asthma Immunol 90:214-22. 2003

Collaborators

Detail Information

Publications11

  1. ncbi Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma
    Joseph M Parker
    MedImmune LLC, Gaithersburg, MD, USA
    BMC Pulm Med 11:14. 2011
    ..Two randomized placebo-controlled studies were conducted to assess the safety profile and potential efficacy of multiple subcutaneous doses of MEDI-528, a humanized anti-IL-9 monoclonal antibody, in asthmatics...
  2. ncbi Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma
    C F LaForce
    North Carolina Clinical Research, Raleigh 27607, USA
    Ann Allergy Asthma Immunol 85:407-15. 2000
    ..Flovent Diskus is a powder formulation of the inhaled corticosteroid fluticasone propionate (FP) delivered via a breath-actuated, multidose inhaler...
  3. ncbi Review of the pharmacology, clinical efficacy, and safety of azelastine hydrochloride
    Craig La Force
    Carolina Allergy and Asthma Consultants, 4301 Lake Boon Trail, Suite 309A, Raleigh, NC 27607, USA
    Expert Rev Clin Immunol 1:191-201. 2005
    ..Azelastine hydrochloride has demonstrated a favorable safety profile during approximately 20 years of clinical use...
  4. ncbi Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis
    Craig F LaForce
    North Carolina Clinical Research, Raleigh, North Carolina 27607, USA
    Allergy Asthma Proc 31:132-40. 2010
    ..Overall, 19 AEs were reported in the OLO + FNS group and 29 AEs were reported in the AZE + FNS group. OLO, when administered adjunctively with FNS, is effective, safe, and well-tolerated in patients with SAR...
  5. ncbi Efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol once daily for the treatment of seasonal allergic rhinitis
    Craig LaForce
    North Carolina Clinical Research, Raleigh, North Carolina 27607, USA
    Ann Allergy Asthma Immunol 103:166-73. 2009
    ..Aerosol-based corticosteroid nasal formulations may be preferred over current aqueous nasal sprays by some patients because they traditionally cause less pharyngeal and anterior nose runoff...
  6. ncbi Patient satisfaction with a pressurized metered-dose inhaler with an integrated dose counter containing a fixed-dose mometasone furoate/formoterol combination
    Craig LaForce
    Department of Pediatrics, University of North Carolina School of Medicine, North Carolina Clinical Research, Raleigh, NC, USA
    J Asthma 48:625-31. 2011
    ....
  7. ncbi Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine
    Craig F LaForce
    Carolina Allergy and Asthma Consultants, Raleigh, North Carolina 27607, USA
    Ann Allergy Asthma Immunol 93:154-9. 2004
    ..Currently available oral second-generation antihistamines do not provide adequate symptom relief for many allergy patients...
  8. ncbi Montelukast effectively treats the nighttime impact of seasonal allergic rhinitis
    Eli O Meltzer
    Allergy and Asthma Medical Group and Research Center, San Diego, CA 92109, USA
    Am J Rhinol 19:591-8. 2005
    ..In these studies, montelukast significantly improved the NSS, a clinically relevant and valid measure in patients with SAR...
  9. ncbi Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma
    Brian J Lipworth
    Allergy Research Group, Department of Medicine and Therapeutics, University of Dundee, Dundee, Scotland
    Ann Allergy Asthma Immunol 94:465-72. 2005
    ..Ciclesonide (hydrofluoroalkane propellant) is a novel inhaled corticosteroid with few, if any, clinical adverse events...
  10. ncbi Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis
    Janet van Adelsberg
    Merck and Co Inc Rahway, New Jersey, USA
    Ann Allergy Asthma Immunol 90:214-22. 2003
    ..Symptoms of allergic rhinitis are mediated in part by cysteinyl leukotrienes...
  11. ncbi Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids
    William R Lumry
    AARA Research Center, Dallas, TX 75231, USA
    Ann Allergy Asthma Immunol 96:51-9. 2006
    ..Therefore, some metered-dose inhaler products are being reformulated with "ozone-friendly" hydrofluoroalkane propellants...